Browse Studies — Arctuva

Phase 4

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor a…

Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more

Estimated

~$10 – $6,250

Vanderbilt-Ingram Cancer CenterNCT06016855

Phase 2

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)

This phase IIa trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients wit…

Digestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06202066

Phase 1

Combination External Radiation and 177Lu-DOTATATE for Large Gastrointestinal Neuroendocrine Tumors: A Single Arm Pilot Clinical Trial

This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide th…

Digestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more

Estimated

~$10 – $6,250

Emory UniversityNCT07150546